On Wednesday, American Capital Agency Corp (NASDAQ:AGNC)’s shares declined -0.92% to $21.53.
On April 13, American Capital Agency Corp (AGNC), declared that its Board of Directors has declared a cash dividend of $0.22 per share of common stock for April 2015. The dividend is payable on May 8, 2015 to common shareholders of record as of April 30, 2015, with an ex-dividend date of April 28, 2015.
AGNC’s March 31, 2015 net book value per common share will be declared concurrent with the Company’s regular quarterly earnings release, which is planned for April 27, 2015.
American Capital Agency Corp. operates as a real estate investment trust (REIT) in the United States. The company invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by government-sponsored enterprise or by the United States government agency. It funds its investments primarily through short-term borrowings structured as repurchase contracts.
Inovio Pharmaceuticals Inc (NASDAQ:INO)’s shares dropped -0.91% to $10.39, during the last trading session on Wednesday.
On April 9, Inovio Pharmaceuticals Inc. declared that it was recognized with a prestigious industry award at the World Vaccine Congress being held this week in Washington, D.C. The Vaccine Industry Excellence (ViE) Awards honor outstanding vaccine advancements and achievements of therapeutic and preventive vaccine developers across the worldwide industry as judged by a panel of global biotech industry stakeholders.
Inovio was given accolades by its industry peers for “Best Therapeutic Vaccine” for its DNA-based immunotherapy, VGX-3100, which was designed to treat HPV-associated precancers and cancers. In a large, controlled phase II efficacy trial Inovio stated top line data demonstrating regression of disease and clearance of the underlying cause of the condition — the HPV virus. Inovio anticipates to publish the complete data set in a peer-reviewed journal this year, is advancing this product into a phase III trial early next year, and has expanded studies of this immunotherapy to comprise cervical and head and neck cancer.
Each year, the award recognizes the therapeutic vaccine that addresses an unmet medical need and holds noteworthy potential for vast geographical and market reach. This is the third successive year that Inovio’s lead product has won this designation.
Dr. J. Joseph Kim, President and CEO, said, “There is a clear unmet need for a non-surgical option for women with cervical precancers around the world. We greatly appreciate the World Vaccine Congress’ recognition of Inovio’s VGX-3100 potential to address this opportunity.
Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The companys SynCon immunotherapy design has the ability to break the immune systems tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, in addition to new unmatched strains of pathogens, such as influenza.
At the end of Wednesday’s trade, Office Depot Inc (NASDAQ:ODP)‘s shares dipped -0.86% to $9.25.
Yesterday, Office Depot Inc. , which reached a definitive contract on February 4, 2015 to be attaind by Staples Inc., recently declared that it was named to the 16th annual list of America’s Top Corporations for Women’s Business Enterprises (WBEs) by the Women’s Business Enterprise National Council (WBENC). This marks the 13th year that Office Depot has been named to the selective list.
“We are proud to be recognized again for proactively integrating WBEs into our supply chain, validating our commitment to actively conducting business with women-owned businesses that are WBENC-certified,” said Linda Boykin, vice president of merchandising for Office Depot, Inc. “We created our supplier diversity program to give these types of businesses additional opportunities to grow and prosper, and we couldn’t be happier to continue to see them breaking down barriers and becoming successful.”
Making products from diverse suppliers readily accessible and top of mind for business customers is a core focus of Office Depot’s supplier diversity strategy. The Company actively seeks out promising diverse suppliers that are certified minority-, women-, disabled-, LGBT- and veteran-owned to ensure equal opportunity in the supplier selection process.
Office Depot was presented with the America’s Top Corporation award at the WBENC Summit & Salute to Women’s Business Enterprises, which took place March 18-19 in Baltimore.
Office Depot, Inc., together with its auxiliaries, supplies office products and services. The company’s North American Retail division sells an assortment of merchandise, counting office supplies, technology products and solutions, business machines and related supplies, facilities products, and office furniture under various brands through its chain of office supply stores.
Biomed Realty Trust Inc (NYSE:BMR), ended its Wednesday’s trading session with -0.80% loss, and closed at $21.05.
Yesterday, Biomed Realty Trust Inc. declared that its 2014 Online Annual Report and other proxy materials are now accessible at http://www.biomedrealty.com/14AR.
Titled “The Next 10 Years,” the 2014 Online Annual Report explores the company’s outstanding results in 2014 and vision for 2015 and beyond. In addition, the site examines the influence and growth of the life science industry and the value that BioMed Realty brings to the industry by developing, owning and operating the best real estate which create connection points between the industry and the commercial world to turn recently’s innovations into tomorrow’s answers for patient populations across the world.
This year’s online annual report examines the company’s many accomplishments during the past year by leveraging a strategy focused on people, expertise and relationships, counting:
- Generating the highest leasing volume, total revenues and rental revenues in the company’s history for the second successive year;
- Adding about 1.4 million additional rentable square feet of space from planned investments during the year;
- Expanding the company’s university platform, Wexford Science + Technology, with the grand opening of the 3737 Market Street building in the University City Science Center in Philadelphia, Pennsylvania and a 283,000 square foot expansion in the Wake Forest Innovation Quarter in Winston-Salem, North Carolina; and
- Harvesting value from the largest asset disposition in the company’s history and redeploying those proceeds into new investments in core innovation districts with compelling long-term growth prospects.
BioMed Realty Trust, Inc. operates as a real estate investment trust (REIT) that focuses on providing real estate to the life science industry in the United States. Its tenants primarily comprise biotechnology and pharmaceutical companies, scientific research institutions, government agencies, and other entities involved in the life science industry.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
